Nasdaq Grants VYNE Therapeutics Extension to Regain Minimum Bid Price Compliance
VYNE has more than doubled off its 52-week low of $0.281.
Summary
VYNE Therapeutics Inc. received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to September 7, 2026.
Key Events · Corporate Governance and Compliance · VYNE
-
Delisting Deadline Missed
VYNE Therapeutics failed to regain compliance with Nasdaq's minimum $1.00 bid price requirement by the initial March 10, 2026 deadline.
-
Nasdaq Grants Extension
The company received an additional 180 calendar days, until September 7, 2026, to meet the minimum bid price rule.
-
Potential Reverse Stock Split
VYNE Therapeutics indicated it may consider a reverse stock split to cure the bid price deficiency during the extended compliance period.
-
Continued Listing Uncertainty
The stock will continue to trade on Nasdaq for now, but faces potential delisting if compliance is not achieved by the new deadline.
Analysis · VYNE · Life Sciences
This 8-K confirms VYNE Therapeutics failed to meet Nasdaq's minimum bid price requirement by the initial March 10, 2026 deadline. While the granted extension provides a temporary reprieve, it underscores the company's ongoing struggle with its stock price, especially following the highly dilutive reverse merger announced in late February. The company's intention to consider a reverse stock split to cure the deficiency often signals further challenges for existing shareholders. Investors should monitor the stock's performance and any further announcements regarding a reverse split or delisting.
At the time of this filing, VYNE was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20M. The 52-week trading range was $0.28 to $2.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.